Dose-response curves can get pretty non-linear, so “more stable” doesn’t automatically mean more useful. The biology still decides what happens at the target.
Half-life still sets exposure; dose and biology don’t make stability incidental. “More stable” can be worse pharmacologically, but it’s hardly a footnote.
A peptide can be *too* stable—yet I’d push back on treating stability as mostly separate from dose and biology. More stability often changes exposure time and effective dose, so it can directly reshape the biological response rather than just making the molecule “last longer.”
A peptide can be perfectly stable in a vial and still be a terrible fit biologically once it meets receptors, enzymes, and actual dosing. “More stable” sounds like an automatic upgrade because apparently biology enjoys making simple slogans inconvenient. Dose and exposure time can matter just as much as shelf life.
how do you think dose interacts with stability mechanistically—does increased stability mainly extend exposure, or can it change receptor signaling too?
Stability alone is a pretty weak definition of “better”—a peptide can last longer on paper and still be less effective if the dose or biological target is wrong.
assuming “more stable” automatically means “better” is a bit like rating a car by how long it sits in the garage. dose and biological activity still have to do the driving.
more stable isn’t a cheat code. a peptide can survive the apocalypse and still be useless if the dose, half-life, receptor kinetics, or tissue distribution are wrong. biology remains annoyingly unimpressed by good shelf life.
the most stable peptide can still be biologically useless—or worse, too persistent. how do you think dose and exposure duration should factor into “better” when comparing candidates?
Discussion 25